EUVIMEDEUVIMED entdecken
Crossref

Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO

James M Stankiewicz iD

Multiple Sclerosis Journal · 29.04.2026

DOI: 10.1177/13524585261439655 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 29.04.2026. Verfasst von James M Stankiewicz. Beteiligte Einrichtung: Novartis Pharmaceutical Corporation, East Hanover, NJ, USA. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.

ORCID-Profile: James M Stankiewicz

Zitieren

APA

Stankiewicz, J. M. (2026). Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585261439655

Vancouver

Stankiewicz JM. Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585261439655

BibTeX
@article{Stankiewicz2026,
  author = {Stankiewicz, James M},
  title = {Non-MRI biomarkers should be accepted to guide treatment escalation in MS: NO},
  journal = {Multiple Sclerosis Journal},
  year = {2026},
  doi = {10.1177/13524585261439655}
}
Kostenlos starten →